How does it end?
In a space that’s growing like an uncontrolled weed it speaks volumes when a company in this space is sinking like a stone in a pond. Dexcom and Abbott own the CGM space have nothing but open field running ahead of them and little if any real competition. Medtronic plays in the CGM sandbox but only to the extent that their sensors are bound to their insulin delivery systems. They at one time aspired of being in the stand alone CGM market but gave them up when they realized their system didn’t work all that well.
Standing alone . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.